---
title: "First Volunteer Receives Oxford’s Bundibugyo Ebola Vaccine"
url: https://projectchintan.com/article/first-volunteer-receives-oxford-s-bundibugyo-ebola-vaccine-tbxzc8
publisher: Project Chintan
author: Project Chintan Newsroom
section: Health
published: 2026-08-14T13:12:35.143Z
modified: 2026-08-14T16:00:07.125Z
language: en-IN
---

# First Volunteer Receives Oxford’s Bundibugyo Ebola Vaccine

Oxford has dosed the first participant in a 50-person safety study of an experimental Bundibugyo Ebola vaccine. Later trials in Uganda and DR Congo are planned to test it further.

## Key takeaways

- The first vaccination marks the start of human testing, not evidence that the candidate prevents Ebola.
- The 50-person Oxford study focuses on safety and immune response.
- A small Uganda trial and a larger efficacy study in the Democratic Republic of Congo are planned.
- The Serum Institute of India has manufactured 600,000 doses before clinical success has been established.
- The candidate targets Bundibugyo Ebola, which the licensed Zaire Ebola vaccine reportedly does not cover.

## What Happened

The BBC reported on 24 July 2026 that Ed Hunt, a 37-year-old UK resident, became the first person to receive Oxford’s experimental vaccine against Bundibugyo Ebola. He was vaccinated in Oxford as part of a phase-one study recruiting 50 healthy adults aged 18 to 55.

The study will assess safety and measure whether the candidate generates a strong immune response. It is not designed to establish that the vaccine prevents Ebola. Professor Teresa Lambe, who led the University of Oxford Ebola vaccine team, said the vaccine cannot cause Ebola and that researchers will not deliberately expose participants to the virus.

Hunt said reports about the Ebola outbreak in the Democratic Republic of Congo motivated him to participate. The BBC reported more than 2,500 confirmed cases and just over 1,000 deaths, although the evidence pack does not provide an official data cutoff or independently sourced totals.

## Why It Matters

The candidate addresses a species-specific vaccination gap. A licensed vaccine targets Zaire Ebola, but the BBC reported that it does not protect against the Bundibugyo species. Four Bundibugyo vaccine candidates were reportedly under development, with Oxford’s becoming the first to enter human testing.

Oxford scientists developed the candidate in eight weeks, but that period does not represent the full research timeline. The vaccine uses the same underlying technology as the Oxford-AstraZeneca Covid-19 vaccine, and Lambe attributed the speed to decades of earlier work.

The Serum Institute of India has already manufactured 600,000 doses. Producing supply before clinical proof could reduce deployment delays if the trials succeed, but use of those doses remains conditional on positive results.

## Key Facts

- The initial Oxford study plans to enroll 50 healthy volunteers between 18 and 55.
- Its objectives are safety assessment and measurement of immune response, not direct proof of protection.
- The candidate cannot give a participant Ebola, according to the Oxford team.
- The vaccine uses the same underlying technology as the Oxford-AstraZeneca Covid-19 vaccine.
- The Serum Institute of India has pre-manufactured 600,000 doses for possible use following successful trials.

## What Happens Next

The Oxford team said a second small study was due to begin in Uganda. That trial would be followed by a larger study in the Democratic Republic of Congo intended to evaluate whether the vaccine protects people from Bundibugyo Ebola.

---
Canonical: https://projectchintan.com/article/first-volunteer-receives-oxford-s-bundibugyo-ebola-vaccine-tbxzc8